Tag : Small Cell Lung Cancer

Latest News

New immunotherapy for metastatic non-small cell lung cancer shows promise in clinical trial

Newsemia
A new type of immunotherapy treatment for metastatic non-small cell lung cancer (NSCLC) is being tested by Missak Haigentz, Jr., MD, medical director of hematology...
Gastroenterology

Study shows disparities in guideline-concordant treatment for NSCLC patients

Newsemia
Lung cancer is the leading cause of cancer-associated deaths in the United States. Non-small cell lung cancer (NSCLC), a group of lung cancers named for...
Latest News

AI could enhance prediction of treatment response among patients with non-small cell lung cancer

Newsemia
Artificial intelligence deep learning algorithms may predict response to systemic treatment for non-small cell lung cancer. Source link...
Latest News

Plasma monitoring of EGFR mutations in NSCLC may help predict resistance to tyrosine kinase inhibitors

Newsemia
Oncotarget Volume 11, Issue 11 reported that at clinical progression, 64 EGFR T790M plasma positive patients were subjected to second line-treatment with osimertinib and strictly...
Latest News

Administering immunotherapy alongside chemoradiation for advanced NSCLC appears to be safe and tolerable

Newsemia
Research from Rutgers Cancer Institute of New Jersey shows administering the immunotherapy drug pembrolizumab together with chemotherapy given at the same time as radiation treatment...
Gastroenterology

HIMC at Mount Sinai to evaluate therapeutic effects of novel cancer immunotherapy

Newsemia
The Human Immune Monitoring Center at the Icahn School of Medicine at Mount Sinai will apply cutting-edge high-throughput technologies to evaluate the therapeutic effects of...
Latest News

Higher levels of genetic mutations linked to improved outcomes in lung cancer patients

Newsemia
According to new findings by Yale Cancer Center scientists, higher levels of genetic mutations in a tumor biopsy are linked to improved clinical outcomes in...
Latest News

Dacomitinib treatment for lung cancer increases overall survival but has more side effects

Newsemia
Since its approval in April 2019, dacomitinib has been available for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung...
Latest News

Alternate cell growth pathway could open door to new treatments for metastatic cancers

Newsemia
While researchers have a basic understanding of how primary cancer cells grow, less is known about metastasis, the deadly process by which cancers spread. Source...
Latest News

NCCN and AstraZeneca collaborate to improve care processes for lung cancer patients

Newsemia
The National Comprehensive Cancer Network Oncology Research Program and AstraZeneca, a global, science-led biopharmaceutical company, are collaborating to seek proposals for improving care processes for...
Latest News

Study finds disparities in lung cancer treatments among Asian communities

Newsemia
study from the University of Southern California, Keck School of Medicine, sought to examine possible health disparities in the treatment of lung cancer within the...
Latest News

High-dose standard radiation treatment well-tolerated by patients with centrally located NSCLC

Newsemia
Stereotactic Body Radiotherapy, a high-dose, precisely delivered radiotherapy, is considered the standard treatment for patients with medically inoperable, node-negative, non-small cell lung cancer. Source link...
Latest News

Prophylactic cranial irradiation used as standard approach for patients with NSCLC

Newsemia
Prophylactic cranial irradiation, a technique used to prevent the clinical development of brain metastases, is established as a standard approach for many patients with small...
Latest News

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Newsemia
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with...
Gastroenterology

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

Newsemia
Takeda Pharmaceutical Company Limited today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line)...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy